Indian stock news
On July 3, 2026, Sun Pharmaceutical Industries Limited announced that it has received final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for a generic version of a high--demand oncology medication. The drug, indicated for the treatment of advanced--stage solid tumors, has an estimated annual market size of $450 million in the United States. The company plans to initiate an immediate commercial launch, further strengthening its specialty medicines portfolio and driving revenue growth in the North American market.